In 2008, the Houchen group proposed that DCLK1 is a specific marker protein for intestinal adenoma stem cells [13], which brought attention to DCLK1 in cancer research and was the first of a series of research reports providing evidence that it might be an effective target for oncology drug development. The gene discussed is DCLK1; the disease is cancer.